Rein Therapeutics (NASDAQ:RNTX) Insider James Brian Windsor Purchases 25,000 Shares of Stock

Rein Therapeutics Inc. (NASDAQ:RNTX – Get Free Report) insider James Brian Windsor bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were acquired at an average price of $1.00 per share, with a total value of $25,000.00. Following the acquisition, the insider owned 27,046 shares of the company’s stock, valued at $27,046. This represents a 1,221.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Rein Therapeutics Stock Up 3.6%

Shares of Rein Therapeutics stock opened at $1.16 on Thursday. The company has a market cap of $32.53 million, a PE ratio of -0.59 and a beta of 1.42. The business has a 50 day moving average of $1.38 and a 200 day moving average of $1.34. Rein Therapeutics Inc. has a 52 week low of $1.00 and a 52 week high of $2.40.

Get Rein Therapeutics alerts:

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP purchased a new position in Rein Therapeutics during the 3rd quarter valued at about $35,000. HRT Financial LP purchased a new position in Rein Therapeutics during the 4th quarter valued at about $38,000. Chicago Partners Investment Group LLC lifted its position in Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock valued at $53,000 after acquiring an additional 10,000 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in Rein Therapeutics during the 2nd quarter valued at about $68,000. Finally, Jane Street Group LLC purchased a new position in Rein Therapeutics during the 4th quarter valued at about $72,000. 90.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RNTX. Weiss Ratings restated a “sell (e+)” rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. Citigroup downgraded Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. Finally, downgraded Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Rein Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Check Out Our Latest Stock Report on Rein Therapeutics

About Rein Therapeutics

(Get Free Report)

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.

See Also

• Five stocks we like better than Rein Therapeutics
• Affirm’s Google Deal Aims for Your Wallet
• Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar
• Oklo Stock Could Be Ready for Another Massive Run
• D-Wave Earnings Looked Weak, But Investors May Be Missing This

Receive News & Ratings for Rein Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rein Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.